WELCOME TO The PHARMACEUTICAL REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
MEI Pharma | September 04, 2020
MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the following upcoming virtual investor conferences: NETGEAR Orbi Pro WiFi 6 Tri-band Mesh System Brings the Ultimate WiFi Experience to Small Businesses MEI Pharma, Inc. (NASDAQ: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma's portfolio of drug candidates ...
Omnicell, Inc. | December 30, 2021
Omnicell, Inc. a leading provider of medication management solutions and adherence tools for health systems and pharmacies, has completed the previously announced acquisition of ReCept Holdings, Inc. The addition of ReCept’s specialty pharmacy management services for health systems, provider groups, and federally qualified health centers expands Omnicell’s Advanced Services portfolio to address the growing and complex specialty pharmacy market.
ReCept provides implemen...
Greenmarketreport | April 22, 2020
Tetra Bio-Pharma Inc. (OTCQB:TBPMF) announced its Orphan Drug development strategy and provided a management update. The company said it is focusing on generating intellectual property including use, manufacturing, and innovative molecule protection. Tetra said it received a U.S. Food and Drug Administration (FDA) Orphan Drug Designation for secondary cannabidiol (CBD) formulation of its cannabinoid topical drug PPP004 in the treatment of epidermolysis bullosa. “Each ODD application is dri...
BioPharma Dive: | March 17, 2020
Late last year, New Jersey drugmaker Amarin won a long-sought U.S. approval for its pill Vascepa, allowing the company to market the drug for reducing heart risk. It was a major milestone for the company, validating the decision to run a lengthy and expensive cardiovascular outcomes study, which had delivered positive results in 2018. Eager to sell the drug to a now much wider group of patients, Amarin doubled the number of sales representatives it employs to reach out to doctors and other healt...
RESEARCH, BUSINESS INSIGHTS
BUSINESS INSIGHTS, PHARMA TECH
BUSINESS INSIGHTS, PHARMACY MARKET
RESEARCH, PHARMACY MARKET
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the
community for FREE